NO121047B - - Google Patents
Download PDFInfo
- Publication number
- NO121047B NO121047B NO17002467A NO17002467A NO121047B NO 121047 B NO121047 B NO 121047B NO 17002467 A NO17002467 A NO 17002467A NO 17002467 A NO17002467 A NO 17002467A NO 121047 B NO121047 B NO 121047B
- Authority
- NO
- Norway
- Prior art keywords
- ether
- general formula
- chlorine
- fluorine
- acetic acid
- Prior art date
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 238000005672 Willgerodt-Kindler rearrangement reaction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- SHYRNAJCPIECFE-UHFFFAOYSA-N 1-(2-anilinophenyl)ethanone Chemical class CC(=O)C1=CC=CC=C1NC1=CC=CC=C1 SHYRNAJCPIECFE-UHFFFAOYSA-N 0.000 description 2
- WCSGSHPFLOUHDV-UHFFFAOYSA-N 1-[2-(2,6-dichloroanilino)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl WCSGSHPFLOUHDV-UHFFFAOYSA-N 0.000 description 2
- LZHUTAUPAKOTFY-UHFFFAOYSA-N CCO[Mg].CCOC(=O)CC(=O)OCC Chemical compound CCO[Mg].CCOC(=O)CC(=O)OCC LZHUTAUPAKOTFY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- -1 [2-(2,6 -dichloro-m-toluidino)-5-chlorophenyl]-acetic acid Chemical compound 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- QNBAUJSVBGIPMZ-UHFFFAOYSA-N 1-[2-(2,6-dimethylanilino)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1NC1=C(C)C=CC=C1C QNBAUJSVBGIPMZ-UHFFFAOYSA-N 0.000 description 1
- MJBVSNAREWNIBQ-UHFFFAOYSA-N 1-[2-(3-chloro-2-methylanilino)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1NC1=CC=CC(Cl)=C1C MJBVSNAREWNIBQ-UHFFFAOYSA-N 0.000 description 1
- CQWSKOHCXHLFHZ-UHFFFAOYSA-N 2-(2,6-dichloroanilino)benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl CQWSKOHCXHLFHZ-UHFFFAOYSA-N 0.000 description 1
- GZRAEWKMFPWXNW-UHFFFAOYSA-N 2-[2-(2,6-dichloro-3-methylanilino)phenyl]acetic acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)CC(O)=O)=C1Cl GZRAEWKMFPWXNW-UHFFFAOYSA-N 0.000 description 1
- VGSBGWCOTSSGQY-UHFFFAOYSA-N 2-[2-(2,6-diethylanilino)phenyl]acetic acid Chemical compound CCC1=CC=CC(CC)=C1NC1=CC=CC=C1CC(O)=O VGSBGWCOTSSGQY-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- LJPIGDQQWFXJBF-UHFFFAOYSA-N diethyl 2-(2-anilinobenzoyl)propanedioate Chemical class C(C)OC(C(C(=O)OCC)C(C=1C(NC2=CC=CC=C2)=CC=CC=1)=O)=O LJPIGDQQWFXJBF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Fremgangsmåte for fremstilling av hittil ukjente, substituerte fenyleddiksyrer med terapeutisk virkning. Process for the production of hitherto unknown, substituted phenylacetic acids with therapeutic effect.
Nærværende oppfinnelse vedrorer en fremgangsmåte for fremstilling av hittil ukjente, substituerte fenyleddiksyrer med den generelle formel (I), hvor og FLj uavhengig av hverandre betyr en metyl- eller etylgruppe, eller et fluor-, klor- eller bromatom, The present invention relates to a process for the production of hitherto unknown, substituted phenylacetic acids with the general formula (I), where and FLj independently of each other mean a methyl or ethyl group, or a fluorine, chlorine or bromine atom,
R^betyr hydrogen, en metyl- eller etylgruppe, eller et fluor-, klor- eller bromatom , og R^ represents hydrogen, a methyl or ethyl group, or a fluorine, chlorine or bromine atom, and
R^betyr et hydrogen-, fluor-, klor- eller bromatom. R 2 represents a hydrogen, fluorine, chlorine or bromine atom.
Fremgangsmåten består i at man oppvarmer en forbindelse med den generelle formel (II), The method consists in heating a compound with the general formula (II),
hvor R-p R2, R^og R^har de under formel (I) angitte betydninger, etter Willgerodt-Kindlers metode med svovel og morfolin, og hydrolyserer det forst erholdte morfolid med den generelle formel where R-p R2, R^ and R^ have the meanings indicated under formula (I), according to Willgerodt-Kindler's method with sulfur and morpholine, and hydrolyze the first obtained morpholide with the general formula
III),III),
hvor R-p R£, R^ og R^har de under formel (I) angitte betydninger. F.eks. koker man de nevnte reaksjonskomponenter i overskudd av morfolin noen tid, f.eks. ca. ^ - hO timer under tilbakelop, skiller fra det dannede morfolid av thiosyren og hydrolyserer det f.eks. ved koking med etanolisk eller metanolisk natron-eller kalilut. where R-p R£, R^ and R^ have the meanings indicated under formula (I). E.g. the aforementioned reaction components are boiled in an excess of morpholine for some time, e.g. about. ^ - hO hours under reflux, separates from the formed morpholide the thio acid and hydrolyzes it, e.g. by boiling with ethanolic or methanolic caustic soda or potash.
De som utgangsstoffer nodvendige forbindelser med den generelle formel (II), substituerte o-anilino-acetofenoner, fremstilles f.eks. ved å gå ut fra tilsvarende substituerte N-fenyl-anthranil-syrer, av hvilke representanter er kjent og ytterligere er frem-stillbare analogt de kjente. De nevnte substituerte N-fenyl-anthranilsyrer overfores forst til deres syreklorider og de sistnevnte omsettes med (etoksymagnesium)-malonsyredietylester i absolutt etanol, hvorved man oppnår substituerte (N-fenyl-anthraniloyl)-malonsyre-dietylestere. Fra disse dannes ved koking i surt medium, f.eks. ved koking i en blanding av svovelsyre og vandig eddiksyre under hydrolyse og etterfølgende av-spaltning av 2 molekyler karbondioksyd de onskede substituerte o-anilino-acetofenoner med den generelle formel (II). The compounds with the general formula (II), substituted o-anilino-acetophenones, which are required as starting materials, are prepared, e.g. by proceeding from correspondingly substituted N-phenyl-anthranilic acids, representatives of which are known and can further be produced analogously to the known ones. The mentioned substituted N-phenyl-anthranilic acids are first transferred to their acid chlorides and the latter are reacted with (ethoxymagnesium)-malonic acid diethyl ester in absolute ethanol, whereby substituted (N-phenyl-anthraniloyl)-malonic acid diethyl esters are obtained. From these is formed by boiling in an acidic medium, e.g. by boiling in a mixture of sulfuric acid and aqueous acetic acid during hydrolysis and subsequent splitting off of 2 molecules of carbon dioxide the desired substituted o-anilino-acetophenones of the general formula (II).
Som det videre ble funnet, innehar de nye syrer med den generelle formel (I) verdifulle terapeutiske egenskaper, spesielt anti-flogistisk (anti-inflammatorisk), analgetisk og antipyretisk virkning ved gunstig terapeutisk indeks. De kan anvendes oralt eller rektalt for behandling av revmatiske, arthritiske og andre inflammatoriske sykdommer. Den antiflogistiske virkning lar seg påvise i dyreforsok, f.eks. ved UV-Erythem hos marsvin og ved Bolus alba-bdem hos rotter. As was further found, the new acids of the general formula (I) possess valuable therapeutic properties, in particular anti-phlogistic (anti-inflammatory), analgesic and antipyretic action at a favorable therapeutic index. They can be used orally or rectally for the treatment of rheumatic, arthritic and other inflammatory diseases. The antiphlogistic effect can be demonstrated in animal experiments, e.g. in UV-Erythem in guinea pigs and in Bolus alba-bedema in rats.
Forbindelse 1. [b-(2,6-diklor-anilino)-fenyl] - eddiksyreCompound 1. [b-(2,6-dichloro-anilino)-phenyl]-acetic acid
" 2. (p-(2,6-diklor-m-toluidino-fenyl] -eddiksyre " 3. [o-(2,6-xylidino)-feriyi]-eddiksyre " 1+. [2-(2,6-diklor-m-toluidino)-5-klorfenyl] - eddiksyre " 2. (p-(2,6-dichloro-m-toluidino-phenyl)-acetic acid " 3. [o-(2,6-xylidino)-ferriyl]-acetic acid " 1+. [2-(2,6 -dichloro-m-toluidino)-5-chlorophenyl]-acetic acid
" 5-[p-(2,6-diklor-anilino)-fenyl] - eddiksyre (ifolge fransk medisinsk patent nr. h 2M+ M). " 5-[p-(2,6-dichloro-anilino)-phenyl]-acetic acid (according to French medical patent no. h 2M+ M).
Den nedenstående undersøkelsesmetode ble anvendt og de angitte resultater oppnådd. The research method below was used and the stated results obtained.
Bolus alba- bdem hos rotterBolus alba- bdem in rats
(Wilhelm!, G., Japanese J. Pharmacol. 15, (196?) 187-198)(Wilhelm!, G., Japanese J. Pharmacol. 15, (196?) 187-198)
Som forsbksdyr ble anvendt hvite hanrotter med vekt 110-130 g,White male rats weighing 110-130 g were used as test animals,
6 dyr pr. dose. Forsbkssubstansen administreres oralt som suspensjon med tragant. En time senere utloses ved subkutan injeksjon av 0,1 ml av en 10%{s suspensjon av Bolus alba etbdem i fotsålen på den hbyre bakpote. 5 timer senere drepes rottene og bakpotene amputeres. Svellingen måles ved bestem-melse av vektsdifferansen mellom den venstre, normale pote og den hbyre, svellede pote. Den midlere vekt av svellingen for de med forsbkssubstansen behandlede rotter sammenlignes med den for ubehandlede kontrolldyr. Den med prbvesubstansen oppnådde midlere svellingsreduksjon uttrykkes i %. 6 animals per dose. The test substance is administered orally as a suspension with tragacanth. One hour later, subcutaneous injection of 0.1 ml of a 10% suspension of Bolus alba etbdem is triggered in the sole of the foot on the right hind paw. 5 hours later, the rats are killed and the hind paws are amputated. The swelling is measured by determining the weight difference between the left, normal paw and the right, swollen paw. The mean weight of the swelling for the rats treated with the test substance is compared with that of untreated control animals. The average swelling reduction achieved with the test substance is expressed in %.
Resultatene i foranstående tabell viser den overlegne anti-inflammatoriske virkning for de undersokte forbindelser som fremstilles ifolge nærværende oppfinnelse, i sammenligning med en fra det franske medisinske patent nr. k- 2kh M kjent forbindelse. The results in the preceding table show the superior anti-inflammatory effect of the examined compounds produced according to the present invention, in comparison with a compound known from the French medical patent No. k-2kh M.
Det etterfølgende eksempel redegjor nærmere for gjennomføringen av fremgangsmåten ifolge oppfinnelsen. Temperaturene er angitt i Celsiusgrader. The following example explains in more detail the implementation of the method according to the invention. The temperatures are indicated in degrees Celsius.
EKSEMPELEXAMPLE
Man koker en blanding av 2 g o-(2,6-dikloranilino)-acetofenon, 0,75 g svovel og 2,2 g morfolin i 15 timer under tilbakelop (badtemperatur 150°). Ved avkjøling krystalliserer oppløsningen. Man opploser krystallkaken i 50 ml benzen, filtrerer fra det uoppløselige materiale og inndamper filtratet under 11 Torr til tbrrhet. Det tilbakeblivende h- [ [o-(2,6-dikloranilino)-fenyl]-thio-acetyl]-morfolin opploser man i 50 ml 5$'ig etanolisk natronlut og koker opplosningen i 15 timer under tilbakelop. Deretter avkjoler man opplosningen og inndamper den under 11 Torr ved ^-0° til torrhet. Resten opploser man i 100 ml vann. Den vandige oppløsning ekstraheres med 30 ml eter og surgjores så med 2-n saltsyre. Man opploser den utfelte olje i ^0 ml eter, skiller eteropplosningen fra, vasker den med litt vann, torker den over natriumsulfat og inndamper den til torrhet under 11 Torr. Co-(2,6-dikloranilino)-fenyl3-eddiksyre krystalliserer fra eter-petroleter, smeltepunkt 156-158°. A mixture of 2 g of o-(2,6-dichloroanilino)-acetophenone, 0.75 g of sulfur and 2.2 g of morpholine is boiled for 15 hours under reflux (bath temperature 150°). On cooling, the solution crystallizes. The crystal cake is dissolved in 50 ml of benzene, the insoluble material is filtered off and the filtrate is evaporated below 11 Torr to dryness. The remaining h-[[o-(2,6-dichloroanilino)-phenyl]-thio-acetyl]-morpholine is dissolved in 50 ml of 5% ethanolic caustic soda and the solution is refluxed for 15 hours. The solution is then cooled and evaporated below 11 Torr at ^-0° to dryness. The rest is dissolved in 100 ml of water. The aqueous solution is extracted with 30 ml of ether and then acidified with 2N hydrochloric acid. The precipitated oil is dissolved in ^0 ml of ether, the ether solution is separated, washed with a little water, dried over sodium sulphate and evaporated to dryness below 11 Torr. Co-(2,6-dichloroanilino)-phenyl3-acetic acid crystallizes from ether-petroleum ether, melting point 156-158°.
På analog måte oppnår man £o-(2,6-diklor-m-toluidino)-fenylj-eddiksyre med smeltepunkt ll+6-ll+9° (fra eter-petroleter).In an analogous manner, £o-(2,6-dichloro-m-toluidino)-phenylj-acetic acid is obtained with melting point 11+6-11+9° (from ether-petroleum ether).
De som utgangsstoffer nodvendige, substituerte acetofenoner fremstilles f.eks. på folgende måte: Man tilforer en blanding av 0,2 g absolutt etanol og 0,17 ml karbontetraklorid til 0, 2k g magnesiumspon. Så snart reaksjonen er satt i gang, fortynner man med 20 ml eter. Så tilsetter man en blanding av l, k g malonsyredietylester og 0,8 ml absolutt etanol og oppvarmer blandingen i 3 timer på dampbadet til koking, hvorved magnesiumet går i opplosning under dannelse av (etoksy-magnesium)-malonsyre-dietylester. Man tilsetter til den kokende opplosning en blanding av 2, k g N-(2,6-diklor-fenyl)-anthranil-syreklorid og 5 ml absolutt eter. Etter 15 minutter avkjoler man til 20° og tilsetter fortynnet svovelsyre (0,96 g konsentrert svovelsyre + 8 ml vann). Man ryster blandingen inntil en opplosning dannes. Deretter skiller man fra eterfasen. Den vandige fase ekstraheres med 10 ml eter. Man forener eteropplosningene, torker dem med natriumsulfat og inndamper dem under 11 Torr til torrhet. Den som rest tilbakeblivende rå [N-(2,6-diklorfenyl)-anthraniloylj-malonsyredietylester tilsetter man en blanding av 2, h ml iseddik, 0,32 ml konsentrert svovelsyre og 1,6 ml vann. Man oppvarmer opplosningen i h timer under tilbakelop under koking, avkjoler den til 5° og innstiller den alkalisk ved til-setning av 30$'ig natronlut. Den alkalisk-vandige suspensjon ekstraheres med ml eter. Den eteriske opplosning skilles fra, torkes over natriumsulfat og inndampes under 11 Torr. Resten krystalliserer man fra metanol. Det erholdte o-(2,6-diklor-anilino)-acetofenon smelter ved 115-117°. The substituted acetophenones required as starting materials are produced, e.g. in the following way: A mixture of 0.2 g of absolute ethanol and 0.17 ml of carbon tetrachloride is added to 0.2 k g of magnesium shavings. As soon as the reaction has started, dilute with 20 ml of ether. Then a mixture of 1.5 g of malonic acid diethyl ester and 0.8 ml of absolute ethanol is added and the mixture is heated for 3 hours in the steam bath to boiling, whereby the magnesium dissolves to form (ethoxy-magnesium)-malonic acid diethyl ester. A mixture of 2.0 g of N-(2,6-dichloro-phenyl)-anthranilic acid chloride and 5 ml of absolute ether is added to the boiling solution. After 15 minutes, cool to 20° and add dilute sulfuric acid (0.96 g concentrated sulfuric acid + 8 ml water). The mixture is shaken until a solution is formed. The ether phase is then separated. The aqueous phase is extracted with 10 ml of ether. The ether solutions are combined, dried with sodium sulphate and evaporated to dryness below 11 Torr. A mixture of 2.1 ml of glacial acetic acid, 0.32 ml of concentrated sulfuric acid and 1.6 ml of water is added to the remaining crude [N-(2,6-dichlorophenyl)-anthraniloyl-malonic acid diethyl ester. The solution is heated for h hours under reflux while boiling, cooled to 5° and made alkaline by the addition of 30% caustic soda. The alkaline-aqueous suspension is extracted with ml of ether. The ethereal solution is separated, dried over sodium sulphate and evaporated below 11 Torr. The remainder is crystallized from methanol. The obtained o-(2,6-dichloro-anilino)-acetophenone melts at 115-117°.
På analog måte oppnås o-(2,6-diklor-m-toluidino)-acetofenon, smeltepunkt 10V-106<0>fra metanol. In an analogous manner, o-(2,6-dichloro-m-toluidino)-acetophenone, melting point 10V-106<0>, is obtained from methanol.
På analog måte fremstilles også:In an analogous way, the following are also produced:
a) [o-(2,6-xylidino)-fenylD-eddiksyre, smeltepunkt 133-137°} fra eter-petroleter; ved å gå ut fra o-(2,6-xylidino)-acetofenon; b) [o-(6-klor-o-toluidino)-fenylj-eddiksyre, smeltepunkt l^O-l1+7°, fra eter; ved å gå ut fra o-(6-klor-o-toluidino)-acetofenon; c) L2-(2<*>,6<1->dikloranilino)-5-klorfenylj-eddiksyre, smeltepunkt I8I-I83<0>; ved å gå ut fra 2-(2',6'-dikloranilino)-5-klor-acetofenon; d) C2-(2',6'-diklor-m-toluidino)-5-klorfenyl]- eddiksyre, smeltepunkt 152-156°, fra eter; ved å gå ut fra 2-(2',6'-diklor-m-toluidino)-5-kloracetofenon; e) o-(2',6'-diklor-3'-metylanilino)-fenyleddiksyre, smeltepunkt 1V6-11+90; f) o-(2',6'-dietylanilino)-fenyleddiksyre, smeltepunkt 88-90°. a) [o-(2,6-xylidino)-phenylD-acetic acid, m.p. 133-137°} from ether-petroleum ether; starting from o-(2,6-xylidino)-acetophenone; b) [o-(6-chloro-o-toluidino)-phenylj-acetic acid, m.p. 1^0-11+7°, from ether; starting from o-(6-chloro-o-toluidino)-acetophenone; c) L2-(2<*>,6<1->dichloroanilino)-5-chlorophenylj-acetic acid, melting point I8I-I83<0>; starting from 2-(2',6'-dichloroanilino)-5-chloro-acetophenone; d) C2-(2',6'-dichloro-m-toluidino)-5-chlorophenyl]-acetic acid, m.p. 152-156°, from ether; starting from 2-(2',6'-dichloro-m-toluidino)-5-chloroacetophenone; e) o-(2',6'-dichloro-3'-methylanilino)-phenylacetic acid, melting point 1V6-11+90; f) o-(2',6'-diethylanilino)-phenylacetic acid, melting point 88-90°.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1451766A CH470349A (en) | 1966-10-07 | 1966-10-07 | Process for the production of new substituted phenylacetic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
NO121047B true NO121047B (en) | 1971-01-11 |
Family
ID=4401487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO17002467A NO121047B (en) | 1966-10-07 | 1967-10-06 |
Country Status (12)
Country | Link |
---|---|
AT (1) | AT273935B (en) |
BE (1) | BE704820A (en) |
CH (1) | CH470349A (en) |
DK (1) | DK120243B (en) |
ES (1) | ES345831A1 (en) |
FI (1) | FI47880C (en) |
GB (1) | GB1183968A (en) |
GR (1) | GR37760B (en) |
NL (1) | NL6713629A (en) |
NO (1) | NO121047B (en) |
SE (1) | SE345997B (en) |
YU (1) | YU32369B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU83138A1 (en) * | 1981-02-16 | 1981-09-11 | T Eckert | TOPICAL PHARMACEUTICAL PREPARATIONS, CONTAINING SALTS OF ALKANCARBONIC ACIDS AND NEW CARBONIC ACID SALTS AND METHOD FOR THE PRODUCTION THEREOF |
AT370721B (en) * | 1981-02-24 | 1983-04-25 | Ciba Geigy Ag | METHOD FOR PRODUCING NEW SALTS OF 2- (2,6-DICHLORANILINO) -PHENYLACETIC ACID, THE |
-
1966
- 1966-10-07 CH CH1451766A patent/CH470349A/en not_active IP Right Cessation
-
1967
- 1967-10-04 FI FI265567A patent/FI47880C/en active
- 1967-10-06 NL NL6713629A patent/NL6713629A/xx unknown
- 1967-10-06 BE BE704820D patent/BE704820A/xx unknown
- 1967-10-06 DK DK497867A patent/DK120243B/en not_active IP Right Cessation
- 1967-10-06 YU YU194267A patent/YU32369B/en unknown
- 1967-10-06 GB GB4572467A patent/GB1183968A/en not_active Expired
- 1967-10-06 AT AT910467A patent/AT273935B/en active
- 1967-10-06 SE SE1371067A patent/SE345997B/xx unknown
- 1967-10-06 NO NO17002467A patent/NO121047B/no unknown
- 1967-10-06 GR GR670137760A patent/GR37760B/en unknown
- 1967-10-06 ES ES345831A patent/ES345831A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ES345831A1 (en) | 1968-11-16 |
BE704820A (en) | 1968-04-08 |
SE345997B (en) | 1972-06-19 |
AT273935B (en) | 1969-08-25 |
FI47880B (en) | 1974-01-02 |
FI47880C (en) | 1974-04-10 |
YU194267A (en) | 1974-04-30 |
YU32369B (en) | 1974-10-31 |
GB1183968A (en) | 1970-03-11 |
CH470349A (en) | 1969-03-31 |
DK120243B (en) | 1971-05-03 |
NL6713629A (en) | 1968-04-08 |
GR37760B (en) | 1969-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3784697A (en) | Pharmaceutical composition containing phenoxyalkane-carboxylic acids,salts and esters thereof | |
NO170023B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTICALLY ACTIVE ALFA-GLUCOSIDASE INHIBITORS | |
Hodgson et al. | 382. The diazotisation of aromatic nitro-amines and the prevention of diaryl formation in the Sandmeyer reaction | |
US2489236A (en) | Synthesis of biotin and related compounds | |
NO121047B (en) | ||
NO170024B (en) | PROCEDURE FOR MANUFACTURING ACE INHIBITORS | |
Chiles et al. | OPTICALLY ACTIVE DIAZO COMPOUNDS. II | |
DE2328060C3 (en) | 5-substituted 3-methylbenzo square brackets on square brackets relating to thienyl (2) acetic acids, process for their production and pharmaceutical preparations containing them | |
Blicke et al. | Derivatives of thianaphthene. II | |
US3976673A (en) | 4-Cyclopropylmethyleneoxy-3-chlorophenylacetic acid and salts thereof | |
Canzanelli et al. | Note on the ketonic acid analogous with thyroxine | |
NO131930B (en) | ||
DK147973B (en) | ANALOGY PROCEDURE FOR PREPARING 1,4-DIPHENYL-3-PYRAZOLYL ACETIC ACIDS | |
US3652586A (en) | Process for the production of substituted phenylacetic acids and their esters | |
Gibbons et al. | Polybenzyls from Benzyl Alcohol and Sulfuryl Chloride | |
Burton et al. | 110. The synthesis of some aryl 2-thienyl sulphones and the nitration of thiophen-2-sulphonyl chloride | |
Dibbo et al. | 556. The synthesis of thyroxine and related compounds. Part XVII. The preparation of some additional compounds related to thyroxine | |
US3729559A (en) | 1,2-oxazine derivatives in alleviating pain and treating inflammatory diseases | |
DE1768337B1 (en) | 2-Phenylbenzo [b] thiophene and 2-phenylnaptho [2,3-b] thiophene-3 (2H) -one-1,1-dioxides and process for their preparation | |
CH509307A (en) | Substd phenethylalcohols analgesics anti-inflammatory | |
NO121344B (en) | ||
US1501275A (en) | Ester of 6.8-dimethyl-2-phenylquinoline-4-carboxylic acid and process of producing the same | |
US2864824A (en) | Alkoxy derivatives of 3:5-dioxo-pyrazolidene and process for their manufacture | |
PL62994B1 (en) | ||
Chattaway et al. | CCXXXIII.—The condensation of dichloroacetaldehyde with p-hydroxybenzoic acid |